Document Detail


Benefit of Bivalirudin Versus Heparin After Transradial and Transfemoral Percutaneous Coronary Intervention.
MedLine Citation:
PMID:  22980964     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Bivalirudin, a direct thrombin inhibitor, has been shown to reduce major bleeding and provide a better safety profile compared to unfractionated heparin (UFH) in patients undergoing percutaneous coronary intervention (PCI) through transfemoral access. Data pertaining to the clinical benefit of bivalirudin compared to UFH monotherapy in patients undergoing transradial PCI are lacking. The present study sought to compare the in-hospital net clinical adverse events, including death, myocardial infarction, target vessel revascularization, and bleeding, for these 2 antithrombotic regimens for all patients at a tertiary care, high-volume radial center. From April 2009 to February 2011, all patients treated with bivalirudin were matched by access site to those receiving UFH. The patients in the bivalirudin group (n = 125) were older (72 ± 13 years vs 66 ± 11 years; p <0.0001), more often had chronic kidney disease (51% vs 30%; p = 0.0012), and more often underwent primary PCI (30% vs 14%, p <0.0037) than the UFH-treated patients (n = 125). A radial approach was used in 71% of both groups. The baseline bleeding risk according to Mehran's score was similar in both groups (14 ± 9 vs 15 ± 8, p = 0.48). In-hospital mortality was 2% in both groups (p = 1.00). No difference in net clinical adverse events or ischemic or bleeding complications was detected between the 2 groups. Bivalirudin reduced both ischemic and bleeding events in femoral-treated patients, but no such clinical benefit was observed in the radial-treated patients. In conclusion, as periprocedural PCI bleeding avoidance strategies have become paramount to optimize the clinical benefit, the interaction between bivalirudin and radial approach deserves additional investigation.
Authors:
Jimmy Machaalany; Eltigani Abdelaal; Yoann Bataille; Guillaume Plourde; Pierre Duranleau-Gagnon; Eric Larose; Jean-Pierre Déry; Gérald Barbeau; Stéphane Rinfret; Josep Rodés-Cabau; Robert De Larochellière; Louis Roy; Olivier Costerousse; Olivier F Bertrand
Related Documents :
22955264 - A pilot study of scheduled endoscopic balloon dilation with oral agent tranilast to imp...
15001324 - Therapeutic effect of the combination of etanercept and methotrexate compared with each...
23205334 - A pilot study to investigate the efficacy of tobramycin-dexamethasone ointment in promo...
23304094 - Functional outcomes of patients with sternectomy after cardiothoracic surgery: a case s...
9461974 - Third molar surgical procedures: practices by maxillofacial and oral surgeons in south ...
12825804 - The safety of low-molecular weight heparins for the prevention of thromboembolic events...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-13
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Quebec Heart and Lung Institute, Quebec City, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk factors for coronary artery calcium among patients with chronic kidney disease (from the Chroni...
Next Document:  Fluoroscopy-Induced Chronic Radiation Dermatitis.